Advertisement

ASO Author Reflections: How Should the Patients with Locally Advanced Unresectable Esophageal Cancer Be Treated with Multidisciplinary Approach?

  • Tomoya YokotaEmail author
  • Yuko Kitagawa
ASO Author Reflections
  • 5 Downloads

Notes

Disclosures

Yuko Kitagawa reports conflicts of interest from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Daiichi Sankyo Co., Ltd., Merck Serono Co., Ltd., Asahi Kasei Co., Ltd., EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., Japan Blood Products Organization Medtronic Japan Co., Ltd., Sanofi K. K., grants from Eisai Co., Ltd., Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd.

References

  1. 1.
    National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Esophageal and Esophagogastric Junction Cancers, Version 2.2018. https://www.nccnorg/professionals/physician_gls/pdf/esophagealpdft. Accessed 17 July 2018.
  2. 2.
    Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, ESMO Guidelines Working Group. Oesophageal Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi51–6.CrossRefGoogle Scholar
  3. 3.
    Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.CrossRefGoogle Scholar
  4. 4.
    Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 2015;106:407–12.CrossRefGoogle Scholar
  5. 5.
    Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Br J Cancer. 2016;115:1328–34.CrossRefGoogle Scholar
  6. 6.
    Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2019.  https://doi.org/10.1245/s10434-019-07654-8.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Division of Gastrointestinal OncologyShizuoka Cancer CenterShizuokaJapan
  2. 2.Department of SurgeryKeio University School of MedicineTokyoJapan

Personalised recommendations